Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Cybin Announces Promising Results From Study Measuring Psychedelic Effects on the Brain
“The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics. The possibility of using this technology to develop a predictive tool to aid in identifying appropriate candidates for psychedelic-based therapy is also quite exciting, as is the convenience of a portable device, which could lend itself to more widespread use in clinical settings,” said Doug Drysdale, Chief Executive Officer of Cybin.
Mindset Granted Patent for Lead Drug (But Reunion Also Has Patent)
Mindset Pharma has been granted a U.S. patent for its lead candidate drug, MSP-1014. MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles in pre-clinical studies.
Yet, in a patent law twist, Reunion Neuroscience (formerly Field Trip) was already awarded a patent for the same compound in April of last year. FT-104 (informally known as “Isoprocin Glutarate”).
New Study Shows Psilocybin Increases Music Pleasure in Depression Patients
The relationship between psychedelics and music is not as unidirectional as we might think. While music has been shown to be a valuable aid in psychedelic psychotherapy, it can also be used as a means to obtain concrete evidence of the psychedelics-derived benefits on mood in mental health patients. This was shown by the study illustrated in this article, conducted by a research team at the Imperial College London.
Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
[bsa_pro_ad_space id=2]ADVERTISEMENT
Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in the Netherlands. The trial is being conducted at the Centre for Human Drug Research in Leiden. DMT is a known psychedelic compound that is part of the tryptamine family.
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
PharmaTher has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome. Unpublished results from this study will be evaluated to support a potential Phase 3 clinical study and FDA agreement on a regulatory plan for approval which the Company may pursue.
